AlzeCure Pharma: Positive FDA feedback regarding ACD440 in orphan disease - Redeye
Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regarding the clinical path for ACD440 in the rare pain disorder erythromelalgia.
ANNONS
Redeye comments on yesterday’s news that AlzeCure has received positive feedback from the FDA regarding the clinical path for ACD440 in the rare pain disorder erythromelalgia.